Compare AbbVie Inc (ABBV) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs T Rowe Price Group Inc — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while T Rowe Price Group Inc trades at $117.55 (market cap $25.75B). The key difference: AbbVie Inc is far larger — about 17.5× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.33%). Which is the better fit depends on your goals.
| ABBV | TROW | |
|---|---|---|
Market Cap | $449.91B | $25.75B |
Sector | Health | Financials |
52-Week High | $261.07 | $120.16 |
52-Week Low | $184.85 | $86.19 |
Enterprise Value | $513.38B | $22.45B |
Dividend Yield | 2.72% | 4.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
T. Rowe Price (TROW) trades at $120.16, up 1.36% with bullish technical indicators showing strong momentum above key support levels. The company maintains solid fundamentals with $7.31B revenue, 28.28% net margin, and attractive valuation at 12.78 P/E. Recent earnings beat expectations in Q1 2026, while strategic initiatives in institutional services and AI-focused content demonstrate proactive positioning.
TROW presents a mixed outlook with strong profitability and cash flow generation offset by analyst caution. The stock trades above consensus target ($101.57) but offers dividend appeal with recent $1.30 payout. Key risks include equity outflows and market sensitivity, while institutional enhancements and debt-free balance sheet provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
